electroCore (NASDAQ:ECOR) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

electroCore (NASDAQ:ECOR) announced its quarterly earnings data on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.09, FiscalAI reports. electroCore had a negative net margin of 39.96% and a negative return on equity of 1,956.38%. The company had revenue of $9.45 million for the quarter, compared to analysts’ expectations of $9.49 million.

Here are the key takeaways from electroCore’s conference call:

• Revenue grew 28% year over year to $9.5 million, driven by VA prescription sales of gammaCore and Quell, along with Truvaga growth. Management raised 2026 revenue guidance to more than 30% growth.
• Operating performance improved, with GAAP net loss narrowing to $3.1 million and adjusted EBITDA loss improving 26% year over year to $1.8 million. Management believes the commercial restructuring creates a path to positive adjusted EBITDA in the third quarter of 2027 without a dilutive equity raise.
• Quell was a major growth driver, with second-quarter sales up approximately 700% year over year to $1.3 million. The company is expanding Quell utilization across existing VA accounts and is targeting an FDA submission by year-end for chemotherapy-induced peripheral neuropathy.
• electroCore doubled its sales regions, added 17 independent representatives covering 29 VA medical centers, and is expanding into the Department of Defense, federal workers’ compensation, first responders, and other federal channels. Moving federal supply schedule sales to Lovell Government Services is expected to reduce related costs by roughly 3% of general and administrative expenses and transaction fees.
• Truvaga faced rising competition and advertising costs, with direct cost per click increasing roughly 30% and media efficiency declining. In addition, FDA observations regarding patient-complaint processes will delay a potential Quell 2.0 rebrand and direct-to-consumer relaunch, while VA account concentration remains a risk after a facility staffing issue shifted approximately $145,000 of revenue into the third quarter.

electroCore Trading Up 20.7%

NASDAQ:ECOR traded up $1.39 during trading hours on Friday, hitting $8.09. 213,989 shares of the stock traded hands, compared to its average volume of 67,392. The firm has a 50 day moving average price of $7.69 and a 200 day moving average price of $6.99. The firm has a market cap of $72.97 million, a price-to-earnings ratio of -4.87 and a beta of 0.92. electroCore has a fifty-two week low of $4.16 and a fifty-two week high of $10.49.

Insider Buying and Selling at electroCore

In other electroCore news, Director Thomas J. Errico purchased 9,992 shares of the stock in a transaction dated Thursday, May 21st. The shares were acquired at an average price of $5.99 per share, for a total transaction of $59,852.08. Following the completion of the acquisition, the director owned 360,071 shares of the company’s stock, valued at $2,156,825.29. This represents a 2.85% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joshua S. Lev sold 6,667 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $9.00, for a total value of $60,003.00. Following the transaction, the chief financial officer directly owned 84,889 shares in the company, valued at $764,001. The trade was a 7.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On electroCore

Large investors have recently made changes to their positions in the business. DRW Securities LLC acquired a new stake in shares of electroCore during the fourth quarter worth approximately $264,000. Two Sigma Investments LP boosted its position in electroCore by 20.8% during the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock worth $122,000 after purchasing an additional 4,231 shares during the period. Jane Street Group LLC boosted its position in electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after purchasing an additional 19,599 shares during the period. NewEdge Advisors LLC grew its holdings in electroCore by 857.9% during the first quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after purchasing an additional 145,047 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in electroCore during the first quarter valued at approximately $153,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of electroCore in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $18.00.

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.